Request that the FDA Immediate Administrative and Enforcement Action Against 503B Outsourcing Facilities Distributing Adulterated and Misbranded Ophthalmic Bevacizumab Products | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2026-P-2257

Request that the FDA Immediate Administrative and Enforcement Action Against 503B Outsourcing Facilities Distributing Adulterated and Misbranded Ophthalmic Bevacizumab Products

Documents

Comments

Description

Open

Key Dates

Comment Period OpensMar 4, 2026

Documents

Type	Title	Posted	Comments	Status
Other	Acknowledgement Letter from FDA DMB to Buchanan Ingersoll & Rooney PC	Mar 4, 2026	--

Comment Statistics

Total Comments

Keywords

CDER

Citizen Petition

Buchanan Ingersoll & Rooney PC

Request for Immediate Administrative and

Enforcement Action Against 503B Outsourcing

Facilities Distributing Adulterated and

Misbranded Ophthalmic Bevacizumab Products

OPEN

Data from Regulations.gov